Anti-idiotype antibody vaccine therapy for cancer.
The use of anti-idiotype (Id) antibodies as vaccines to stimulate antitumour immunity is one of several promising immunologic approaches to the therapy of cancer. Extensive studies in animal tumour models have demonstrated the efficacy of anti-Id vaccines in preventing tumour growth and curing mice with established tumours. A number of monoclonal anti-Id antibodies that mimic distinct human tumour-associated antigens (TAAs) have been developed and tested in the clinic, and demonstrate encouraging results. In general, the antigen mimicry by anti-Id antibodies has reflected structural homology in the majority of the cases, and amino acid sequence homology in a few of them. The greatest challenge of immunotherapy by means of anti-Id vaccines is to identify the optimal anti-Id antibody that will function as a true surrogate antigen for a TAA system, and ideally will generate both humoral and cellular immune responses. Although several clinical studies have shown enhanced survival of patients receiving anti-Id vaccines, the efficacy of these vaccines will depend on the results of several randomised Phase III clinical trials that are currently planned or ongoing.
Bhattacharya-Chatterjee
Malaya
M
Department of Internal Medicine and the Barrett Cancer Center, University of Cincinnati, The Vontz Center for Molecular Studies, 3125 Eden Avenue, Cincinnati, OH 45267-0509, USA. malaya.chatterjee@uc.edu
Chatterjee
Sunil K
SK
Foon
Kenneth A
KA
D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use; D004195:Disease Models, Animal; D006801:Humans; D016233:Immunotherapy, Active / Q000379:methods*; D051379:Mice; D009369:Neoplasms / Q000628:therapy*
D000888:Antibodies, Anti-Idiotypic; D019496:Cancer Vaccines